By
Drug Target Review2025-02-11T08:00:20
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T06:15:00Z
Contributor Professor Donald E Ingber, By Drug Target Review
2026-07-08T12:00:00Z
2026-07-08T09:00:00Z
2026-07-08T07:58:00Z
Contributor Dr Nick Lynch, By Dr Raminderpal Singh
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2026-05-12T09:31:00
Contributor Sugish Pillai, Axel Ziemke and Dr Gary Kusdian
2026-06-29T06:49:00
Contributor Laura Alvarez, By Drug Target Review
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
2026-05-22T07:38:00
Contributor Dr Helen Bright, By Drug Target Review
Site powered by Webvision Cloud